PERSONNEL AND READINESS

OFFICE OF THE UNDER SECRETARY OF DEFENSE

4000 DEFENSE PENTAGON WASHINGTON, D.C. 20301-4000

MAR 2 9 2019

MEMORANDUM FOR ASSISTANT SECRETARY OF THE ARMY (MANPOWER & RESERVE AFFAIRS)

ASSISTANT SECRETARY OF THE NAVY (MANPOWER & RESERVE AFFAIRS)

ASSISTANT SECRETARY OF THE AIR FORCE (MANPOWER & RESERVE AFFAIRS)

CHIEF, NATIONAL GUARD BUREAU

SUBJECT: Update to the Department of Defense Drug Testing Panel

Drug abuse by Service members is a safety and readiness issue, and the Department must adapt our detection and deterrence program to address new and emerging drug threats.

Within the next 90 days, fentanyl and norfentanyl will be added to the Drug Demand Reduction Program (DDRP) drug testing panel. Attached are the cutoff concentrations for reporting positive results for these new substances, as well as for other substances on the drug testing panel. Smart testing methods that allow identification of specimens containing these drugs are hereby approved. Such methods include, but are not limited to, mass-spectrometry-based screening, and those methods used to identify specimens containing fentanyl and norfentanyl due to known association with other illicit drugs, such as other opioids and cocaine. All other specimen collection, testing, and the reporting of results under the DDRP must be compliant with guidance in Department of Defense Instruction 1010.16, *Technical Procedures for the Military Personnel Drug Abuse Testing Program*, and will be subject to a medical review process. This will ensure that no adverse disciplinary action will be administered to those who possess a valid medical prescription.

The DDRP will continue to conduct prevalence testing to monitor any change in substance abuse by military personnel. My point of contact for this action is CAPT Eric R. Welsh, USN, at (703) 697-8690 or eric.r.welsh2.mil@mail.mil

James N. Stewart

Assistant Secretary of Defense for Manpower and Reserve Affairs, Performing the Duties of the Under Secretary of Defense for Personnel and Readiness

Attachment: As stated

cc:

Assistant Secretary of Defense for Health Affairs

CUTOFF CONCENTRATIONS IN THE MILITARY DRUG ABUSE TESTING PROGRAM

INITIAL TESTING CUTOFF CONCENTRATIONS

Drug Class	Cutoff Concentration (ng/mL)	
Amphetamines	500	
Benzodiazapines	200	
Cannabinoids (Marijuana)	50	
Synthetic Cannabinoids	10*	
Cocaine Metabolites	150	
Designer Amphetamines	500	
Opioids (Morphine / Codeine)	2,000	
Opioids (Heroin metabolite 6-monoacetylmorphine)	10	
Opioids (Oxycodone / Oxymorphone)	100	
Opioids (Hydrocodone / Hydromorphone)	300	
Opioids (Fentanyl / Norfentanyl)	1.0*	

^{*} Value given is for immunoassay cutoff: may be lower for mass-spectrometry-based screening.

CONFIRMATION CUTOFF CONCENTRATIONS

Initial Presumptive		Cutoff	
Positive Test	Confirmation Drug/Metabolite	(ng/mL)	Reported Drug Use
Amphetamines	Amphetamine	100	d-Amphetamine
	Methamphetamine	100	d-Methamphetamine
Designer Amphetamines	Methylenedioxymethamphetamine	500	MDMA
	Methylenedioxyamphetamine	500	MDA
Benzodiazepines	Lorazepam	100	Lorazepam
	Nordiazepam	100	Nordiazepam
	Oxazepam	100	Oxazepam
	Temazepam	100	Temazepam
	α - hydroxy-alprazolam	100	α - hydroxy-alprazolam
Cannabinoids	Tetrahydrocannabinol-carboxylic acid	15	THC
Synthetic Cannabinoids	Synthetic Cannabinoid Compounds resulting in excretion of:	1.0	SYCAN
	JWH-018-N-pentanoic acid	1.0	SYCAN
	JWH-073-N-butanoic acid	1.0	SYCAN
	UR-144-N-pentanoic acid	1.0	SYCAN
	5-fluoro-PB22-3-carboxyindole	1.0	SYCAN
	MAM-2201-N-pentanoic acid	1.0	SYCAN
	AB-Chminaca metabolite	1.0	SYCAN
	AB-Fubinaca	1.0	SYCAN
	AB-Pinaca metabolite	1.0	SYCAN
Cocaine Metabolites	Benzoylecgonine	100	Cocaine
Opioids	Morphine	4,000	Morphine
	Codeine	2,000	Codeine
	6-monacetylmorphine	10	Heroin
	Oxycodone	100	Oxycodone
	Oxymorphone	100	Oxymorphone
	Hydrocodone	100	Hydrocodone
	Hydromorphone	100	Hydromorphone
Opioids, Cocaine	Fentanyl	1.0	Fentanyl
Metabolites	Nor-fentanyl	1.0	Norfentanyl